Status:
COMPLETED
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
20-64 years
Phase:
PHASE3
Brief Summary
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
Eligibility Criteria
Inclusion
- Patients satisfying the Rome II Diagnostic Criteria.
- Patients in whom no organic changes were observed in large intestine.
Exclusion
- Patients have diseases which interfere with evaluation of the efficacy and safety in this study.
- Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00189696
Last Update
October 12 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chubu Region, Japan
2
Kanto Region, Japan
3
Shikoku Region, Japan
4
Tohoku Region, Japan